Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : SNYNF crawled date : 2021 - 10 - 22 save search
Smooth Sailing for Regeneron and LEO Pharma in Phase III
Published: 2021-10-22 (Crawled : 17:00) - biospace.com/
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
SNY | News | $49.085 5.31% 1.2M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
leo pharma
BioSpace Movers & Shakers, Oct. 22
Published: 2021-10-22 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
LLY | News | $724.615 -1.04% 480K
|
Health Technology
|
| O: -0.09%
H: 1.28%
C: 1.16%
ABT | News | $106.535 -0.33% 510K
|
Health Technology
|
| O: 0.37%
H: 1.06%
C: 0.96%
SNY | News | $49.085 5.31% 1.2M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
OCUL | News | $4.32 -7.0% 700K
|
Health Technology
|
| O: -27.15%
H: 0.89%
C: -12.42%
NRIX 6 d | $12.95 -5.82% 61K
|
Health Technology
|
| O: 0.43%
H: 0.11%
C: -0.81%
GILD | $65.85 -1.83% 2M
|
Health Technology
|
| O: 0.24%
H: 0.0%
C: 0.0%
space spac
ProMIS Neurosciences Appoints Accomplished Biotech Executive, Dr. Maggie Shafmaster, to its Board of Directors
Published: 2021-10-22 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
SNY | News | $49.085 5.31% 1.2M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
biotech iot
Click Therapeutics Completes $52 Million Series B Financing Co-Led by H.I.G. BioHealth Partners and Accelmed Partners
Published: 2021-10-22 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
SNY | News | $49.085 5.31% 1.2M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers
Published: 2021-10-22 (Crawled : 11:00) - biospace.com/
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
TAK | News | $13.115 -0.87% 260K
|
Health Technology
|
| O: 0.07%
H: 0.5%
C: 0.29%
SNY | News | $49.085 5.31% 1.2M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
therapy
Dupixent® (dupilumab) is the first biologic to significantly reduce itch and skin lesions in Phase 3 trial for prurigo nodularis, demonstrating the role of type 2 inflammation in this disease
Published: 2021-10-22 (Crawled : 09:00) - biospace.com/
SNYNF | News | $94.0 -0.27% 0
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
SNY | News | $49.085 5.31% 1.2M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
REGN | News | $894.9 -1.28% 80K
|
Health Technology
|
| O: 0.37%
H: 0.0%
C: 0.0%
disease phase 3 skin trial dupixent
Gainers vs Losers
| 46% | 54% |
Top 10 Gainers
SGBX | $0.26 80.43% 54M
|
Producer Manufacturing
LICN | $1.0 78.57% 3.3M
|
CSSE 4 | $0.2656 74.39% 9.7M
|
Consumer Services
BRFH 4 | $1.89 71.82% 32M
|
Manufacturing
ACON | $0.49 70.14% 24M
|
n/a
BOF | $1.95 66.67% 920K
|
MTC | $3.62 61.61% 790K
|
Technology Services
AMST | $3.22 61.0% 720K
|
Technology Services
PCSA | $2.28 40.74% 37M
|
Producer Manufacturing
EVA | $0.626 39.14% 2.3M
|
Process Industries
Your saved searches
Save your searches and get alerts when important news are released.